TY - JOUR T1 - LONGITUDINAL OVARIAN RESERVE CHANGES IN WOMEN WITH BREAST CANCER RECEIVING ADJUVANT CHEMOTHERAPY OR TAMOXIFEN-ALONE JF - medRxiv DO - 10.1101/2020.06.21.20136689 SP - 2020.06.21.20136689 AU - Shari B Goldfarb AU - Volkan Turan AU - Giuliano Bedoschi AU - Enes Taylan AU - Nadia Abdo AU - Tessa Cigler AU - Heejung Bang AU - Sujita Patil AU - Maura N Dickler AU - Kutluk H Oktay Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/25/2020.06.21.20136689.abstract N2 - Background To determine the longitudinal impact of adjuvant chemotherapy and tamoxifen-only treatments on ovarian reserve by serum anti-Mullerian hormone (AMH) levels in women with breast cancer.Methods One-hundred-and-forty-two women with a primary diagnosis of breast cancer were prospectively followed with serum AMH assessments before the initiation, and 12, 18 and 24 months after the completion of adjuvant chemotherapy or the start of tamoxifen-only treatment. The chemotherapy regimens were classified into Anthracycline-Cyclophosphamide-based (AC-based) and Cyclophosphamide-Methotrexate+5-Fluorouracil (CMF). Longitudinal data were analyzed by mixed effects model for treatment effects over time, adjusting for baseline age and BMI.Results Both chemotherapy regimens resulted in significant decline in ovarian reserve compared to the tamoxifen-only treatment (p<0.0001 either regimen vs. tamoxifen for overall trend). AMH levels sharply declined at 12 months but did not show a significant recovery from 12 to 18 and 18 to 24 months after the completion of AC-based or CMF regimens. The degree of decline did not differ between the two chemotherapy groups (p=0.53). In contrast, tamoxifen-only treatment did not significantly alter the age-adjusted serum AMH levels over the 24-month follow up. Likewise, the use of adjuvant tamoxifen following AC-based regimens did not affect AMH recovery.Conclusions Both AC-based and CMF regimens significantly compromise ovarian reserve, which does not recover during the 12-24-month post-chemotherapy follow up. In contrast, tamoxifen treatment does not seem to alter ovarian reserve. This novel information should be valuable for fertility preservation counselling and in assessing future reproductive potential of breast cancer survivors.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT00823654Funding StatementThis study was supported by RO1 HD053112 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and National Cancer Institute. H. Bang is partly supported by the National Institutes of Health through grant UL1 TR001860. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Boards at all participating institutions (clinicaltrials.gov identifier NCT00823654)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is available if corresponding author approves. ER -